Background/Aims: High sodium intake is implicated in contributing to progression of chronic renal failure. We studied the effect of high sodium consumption on progression of rat experimental renal failure while sodium-induced hypertension was pharmacologically controlled. Methods: 64 Sprague-Dawley rats underwent 5/6 nephrectomy. Subsequently, they were divided in three groups which were fed either low, normal, or high sodium diet. Only the high sodium-consuming group developed hypertension. This group was further divided in two subgroups in which hypertension was either untreated or titrated to normotension by hydralazine alone or with propranolol. Results: Sequential GFR values did not differ between the respective normotensive groups. Survival downslopes of all three normotensive groups (including the pharmacologically treated, high sodium-consuming subgroup) were also similar, extending over 10 weeks. By contrast, pharmacologically untreated animals exhibited severe hypertension and 100% mortality within 3 weeks. In all experimental groups, 24-hour urinary sodium excretion paralleled sodium intake. Proteinuria rose similarly and significantly in all animals on high sodium. A significant correlation between 24-hour sodium and proteinuria was evident throughout the experimental period. Conclusions: (1) In 5/6 nephrectomized rats, renal function deterioration was not affected by dietary sodium, provided hypertension was pharmacologically controlled. (2) Enhanced proteinuria secondary to high sodium consumption had no adverse effect on progression of renal failure in this model.

Keywords:
Sodium intake, Chronic renal failure, Proteinuria, Glomerular filtration rate, Hypertension, hemodynamics
1.
Reid R, Lindop G, Brown W, Lever AF, Lucie N, Webb D: Similar blood pressure but different outcome in rats with DOC and post DOC hypertension. J Hypertens 1983;1:303–310.
2.
Tobian L, Hanlon S: High sodium chloride diets injure arteries and raise mortality without raising blood pressure. Hypertension 1990;15:900–1003.
3.
Schmieder RE, Beil AM: Salt intake and cardiac hypertrophy; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, ed 2. New York, Raven Press, 1995, pp 1327–1333.
4.
Liebson P, Pineas R, Graudits G, Dianzumba S, Grimm R: Variables associated with regression of left ventricular mass in the treatment of mild hypertension. Circulation 1992;86:559–562.
5.
Benstein JA, Parker M, Feiner MD, Dworkin LD: Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 1990;258:F1675–F1681.
6.
Griffin KA, Picken MM, Bidani AK: Deleterious effect of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995;96:793–800.
7.
Lax DS, Benstein JA, Tolbert E, Dworkin LD: Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int 1992;41:1527–1534.
8.
Nankivell BJ, Fawdry RM, Harris DCH: Assessment of glomerular filtration rate in small animals by intraperitoneal 99mTc-DTPA. Kidney Int 1992;41:450–454.
9.
Perry IJ, Beevers DG: Salt intake and stroke, a possible direct effect. J Hum Hypertens 1992;6:23–25.
10.
Xie JX, Sasaki S, Tossens JV, Kesteloot H: The relationship between urinary cations obtained from the Intersalt study and cerebrovascular mortality. J Hum Hypertens 1992;6:17–21.
11.
Dworkin LD, Grosser M, Feiner HD, Ullian M, Parker M: Renal vascular effects of antihypertensive therapy in uninephrectomized spontaneously hypertensive rats. Kidney Int 1989;35:790–798.
12.
Neugarten J, Kaminetski B, Feiner H, Shacht RU, Liu DT, Baldwin DS: Nephrotoxic serum nephritis with hypertension: Amelioration by antihypertensive therapy. Kidney Int 1985;28:135–139.
13.
Dworkin LD, Feiner HD, Randazzo J: Glomerular hypertension and injury in desoxycorticosterone salt rats on antihypertensive therapy. Kidney Int 1987;31:718–724.
14.
Anderson S, Renke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension. J Clin Invest. 1986;77:1993–2000.
15.
Yoshida Y, Kamamura T, Ikoma M, Fogo A, Ichikawa I: Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989;36:626–635.
16.
Dworkin LD, Feiner HD, Parker M, Tolbert E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized spontaneously hypertensive rats. Kidney Int 1991;39:1112–1117.
17.
Dworkin LD, Tolbert E, Recht PA, Nersch JC, Feiner H, Leviur I: Effects of amlodipine on glomerular filtration, growth and injury in experimental hypertension. Hypertension 1996;27:245–250.
18.
Blithe WB: Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 1985:A50–A56.
19.
Griffin KA, Picken MM, Churchill M, Churchill P, Bidani AK: Functional and structural correlate of glomerulosclerosis after renal mass ablation. J Am Soc Nephrol 2000;11:497–506.
20.
Weir MR, Dworkin LD: Antihypertensive drugs, dietary salt and renal protection. How low should you go and with which therapy? Am J Kidney Dis 1998;32:1–22.
21.
Aviv A, Hollenberg N, Weder A: Sodium glomerulopathy: Tubuloglomerular feedback and renal injury in African Americans. Kidney Int 2004;65:361–368.
22.
Weir MR, Dengel DR, Behreus MT, Goldberg AP: Salt induced increases in systolic blood pressure affect hemodynamics of hypertension. Hypertension 1995;25:1334–1339.
23.
Dworkin LD, Benstein JA, Tolbert E, Feiner HD: Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease. J Am Soc Nephrol 1996;7:437–442.
24.
Van Paasen P, de Zeeuw D, Navis G, de Youg P: Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? Hypertension 1996;27:202–208.
25.
Jesus E: Vasoactive hormones and renal sclerosis. Kidney Int 1996;49:578–597.
26.
Bakris GL, Weir MR: Salt intake and reduction in arterial pressure and proteinuria. Am J Hypertens 1996;9:200S–206S.
27.
Antonios TFT, MacGregor GA: Salt – more adverse affects. Lancet 1996;348:250–251.
28.
Hettinger U, Lukasova M, Lewika S, Hilgenfeldt U: Regulatory effects of salt diet on renin-angiotensin-aldosterone and kallikrein-kinin system. Int Immunopharmacol 2002;2:1975–1980.
29.
Ledingham JM, Simpson F, Kamada M: Salt appetite, body sodium, handling of a NaCl loss, renin and aldosterone in genetically and spontaneously hypertensive rats. J Cardiovasc Pharmacol 1990;16(suppl 7):6–8.
30.
Boghossian S, Nzang Nguema G, Jourdan D, Alliot J: Old and mature LOU/c/jall rats enhance protein selection in response to a protein deprivation. Exp Gerontol 2002;37:1431–1440.
31.
De Vinuesa SG, Luno J, Gomez-Campdera F, Ridao N, Sanchez M, Dall Anese C, Valderrabano F: Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs. Nephrol Dial Transplant 2001;16:78–81.
32.
Giatras I, Lav J, Levey A: Effect of angiotensin converting enzyme inhibitors on progression of non diabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997;127:337–345.
33.
Wilmer W, Rovin B, Hebert C, Rao S, Kumor K, Hebert L: Management of glomerular proteinuria. J Am Soc Nephrol 2003;14:3217–3232.
34.
Takamitsu Y, Nakanishi T, Nishihara F, Hasuike Y, Izumi M, Inoue T, Hiraoka K, Itahana R, Miyagawa K: A nitric oxide generating β-blocking agent prevents renal injury in the rat remnant kidney model. Nephron Physiol 2003;93:42–50.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.